Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abercrombie & Fitch Co. (ANF) vs Koninklijke Philips NV (PHG) Price & Performance

Abercrombie & Fitch Co.Trade
Koninklijke Philips NVTrade

Price performance (Past 24H)

Key statistics

Abercrombie & Fitch Co. vs Koninklijke Philips NV — how do they compare? Abercrombie & Fitch Co. trades at $118.27 (market cap $5.27B), while Koninklijke Philips NV trades at $26.99 (market cap $26.33B). The key difference: Koninklijke Philips NV is far larger — about 5× Abercrombie & Fitch Co.'s market cap, and Koninklijke Philips NV pays a 3.76% dividend while Abercrombie & Fitch Co. pays none. Which is the better fit depends on your goals.

ANFPHG
Market Cap
$5.27B$26.33B
Sector
Consumer CyclicalHealth
52-Week High
$129.85$32.91
52-Week Low
$65.61$25.02
Enterprise Value
$5.94B$32.89B
Dividend Yield
3.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abercrombie & Fitch Co.

Abercrombie & Fitch (ANF) trades at $112.62, up 1.94% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $4.95B and net income of $566.22M, achieving consistent earnings beats in recent quarters. Valuation remains attractive with P/E of 10.89 and EV/EBITDA of 6.54, while profitability metrics show impressive ROE of 39.04% and net margin of 9.34%.

ANF presents a compelling investment case with strong operational performance and reasonable valuation, though technical indicators show overbought conditions. Key risks include retail sector volatility and potential growth headwinds in EMEA markets. Analyst consensus leans neutral with 50% hold ratings, while institutional ownership trends show continued interest from major funds.

Koninklijke Philips NV

PHG trades at $26.73, up 1.52% today, with a bullish technical signal and recent earnings beats in Q4 2025, Q1 2026, and Q2 2026. The company reported $17.83B revenue and $895M net income for 2025, with a P/E of 20.29 and net margin of 6.31%. Recent news highlights Exor increasing its stake and FDA clearances for new health tech products, supporting positive sentiment.

Outlook is cautiously optimistic with strong profitability and institutional interest, but risks include order intake volatility and debt levels. Analysts show 40.9% buy ratings, indicating potential upside if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abercrombie & Fitch Co.

Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.

Read more on ANF

About Koninklijke Philips NV

Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.

Read more on PHG